| 1372485-63-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• CAS: 1372485-63-6
• 化学式: C₃₁H₃₂O₇S
• 分子量: 548.657
• InChiKey: WKGHKABUAPZNTO-SXRBVZPYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.66
• 重原子数：
  39.0
• 可旋转键数：
  6.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  83.45
• 氢给体数：
  1.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  、 菝葜皂苷元 在 N-碘代丁二酰亚胺 、 三氟甲磺酸三甲基硅酯 作用下， 以 二氯甲烷 为溶剂， 反应 0.67h， 生成
  参考文献：
  名称：

  Facile Synthesis and Antitumor Activities of Timosaponin AIII and Its Analogs

  摘要：

  An efficient synthesis of timosaponin AIII (TAIII) and five structurally modified analogs via a one-pot sequential glycosylation strategy is described. A partially protected D-galactopyranosyl thioglycoside was employed for regioselective glycosylation to facilitate the target synthesis. The antitumor activities of the synthetic saponins against human epithelial cervical cancer cell (HeLa) were preliminarily evaluated by means of CCK-8 assay. An L-rhamnosyl analog was discovered to display stronger inhibitory activity (IC50 3.3 mu M) than TAIII (IC50 10.7 mu M) to HeLa cell. Supplemental materials are available for this article. Go to the publisher's online edition of Journal of Carbohydrate Chemistry to view the free supplemental file.

  DOI：

  10.1080/07328303.2011.639966

文献信息

• Efficient Synthesis and Antitumor Activities of Indioside E Analogs
  作者：Yisheng Zhao、Lian An、Guofeng Gu、Zhongwu Guo

  DOI：10.1080/07328303.2014.900564

  日期：2014.3.24

  An efficient synthesis of seven analogs of a naturally occurring saponin, indioside E, is described. The synthesis used a 3,4,6-O-protected D-galactopyranosyl thioglycoside as the key intermediate to enable regioselective glycosylation and one-pot multistep reactions. Antitumor activities of the synthetic saponins against a human hepatocellular carcinoma cell line BEL-7402 and a human breast adenocarcinoma cell line MCF-7 were evaluated by means of the CCK-8 assay. Analogs carrying trisaccharides with the D-xylopyranose in indioside E substituted with a D-ribopyranose and an L-arabinopyranose or with its diosgenin aglycon replaced with tigogenin exhibited similar antitumor activities as indioside E, but not other analogs.